Outcome in adult low-grade glioma: The impact of prognostic factors and treatment

Neurology

Volumn 69, Issue 13, 2007, Pages 1366-1373

  Schiff, David ^a   Brown, Paul D ^b   Giannini, Caterina ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; MOLECULAR MARKER; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; EVIDENCE BASED PRACTICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GLIOMA; HUMAN; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DEPTH DOSE; RADIATION DOSE; REVIEW; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS; DISEASE PROGRESSION; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 34748855654     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000277271.47601.a1     Document Type: Review

References (66)

1. Kleihues P, Cavenee WK. Pathology and genetics of tumors of the nervous system. Lyon, France: IARC Press; 2000.
2. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076-2084.
3. Leighton C, Fisher B, Bauman G, et al. Supratentorial low- grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997;15:1294-1301.
4. Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998;34:98-102.
5. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267-2276.
6. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996;36:549.
7. Shaw EG, Won M, Brachman DG, et al. Preliminary Results of R TOG protocol 9802: a phase II study of observation in completely resected adult low-grade gliomas. World Federation of Neuro-Oncology. Edinburgh, 2005.
8. Buckner JC, Gesme D Jr, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-255.
9. Krouwer HG, Davis RL, Silver P, Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg 1991;74:399-406.
10. Giannini C, Scheithauer BW, Weaver AL, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001;60:248-262.
11. Giannini C, Scheithauer BW, Burger PC, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999;58:46-53.
12. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 1997;41:878-884.
13. Dehghani F, Schachenmayr W, Laun A, Korf HW. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl) 1998;95:493-504.
14. Shimada Y, Kubo O, Tajika Y, Hiyama H, Atuji S, Takakura K. Clinicopathological study of mixed oligoastrocytoma. In: Nagai M, ed. Brain tumor research and therapy. Tokyo: Springer-Verlag, 1997.
15. Prayson RA. The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol 2005;12:144-148.
16. Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 1997;56:857-865.
17. Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 2006;30:657-664.
18. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low- grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berl) 2004;108:49-56.
19. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-489.
20. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355:846-847.
21. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-223.
22. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-530.
23. von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992;52:2987-2990.
24. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 2002;8:1117-1124.
25. Stander M, Peraud A, Leroch B, Kreth FW. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 2004;101:1028-1035.
26. Ishii N, Tada M, Hamou MF, et al. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 1999;18:5870-5878.
27. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neurooncology. J Neuropathol Exp Neurol 2003;62:111-126.
28. Jeuken JW, von Deimling A, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neuro-oncol 2004;70:161-181.
29. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10; p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-9861.
30. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988-994.
31. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-1104.
32. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-95.
33. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-1190.
34. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-319.
35. Eoli M, Bissola L, Bruzzone MG, et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006;119:84-90.
36. Gerson SL. MGMT its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
37. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
38. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
39. McLendon RE, Herndon JE II, West B, et al. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer 2005;104:1693-1699.
40. Buccoliero AM, Arganini L, Ammannati F, et al. Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression. J Chemother 2005;17:321-326.
41. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-385.
42. Dong SM, Pang JC, Poon WS, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001;60:808-816.
43. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2003;144:134-142.
44. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006;106:1759-1765.
45. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985-990.
46. Kortmann RD, Jeremic B, Weller M, Lutterbach J, Paulsen F, Bamberg M. Immediate postoperative radiotherapy or "watch and wait" in the management of adult low-grade glioma? Strahlenther Onkol 2004;180:408-418.
47. Soffietti R, Borgognone M, Ducati A, et al. Efficacy of radiation therapy on seizures in low-grade astrocytomas. World Federation of Neuro-Oncology; 2005; Edinburgh, 2005.
48. Brown PD, Buckner JC, Uhm JH, Shaw EG. The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro-oncology 2003;5:161-167.
49. Laack NN, Brown PD, Ivnik RJ, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 2005;63:1175-1183.
50. Armstrong CL, Hunter JV, Ledakis GE, et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 2002;59:40-48.
51. Vigliani MC, Sichez N, Poisson M, Delattre JY. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys 1996;35:527-533.
52. Torres IJ, Mundt AJ, Sweeney PJ, et al. A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 2003;60:1113-1118.
53. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long- term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360:1361-1368.
54. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996;46:203.
55. Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998;43:1066-1073.
56. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103:802-809.
57. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003;14:1722-1726.
58. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21:646-651.
59. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neuro-oncol 2007;82:281-288.
60. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003;14:1715-1721.
61. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138.
62. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-2528.
63. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
64. Shaw EG, Berkey B, Coons SW, et al. Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG). 2006 ASCO Annual Meeting; 2006; Atlanta, 2006; Abstract 1500.
65. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
66. Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 2004;63:904-906.